Reduced-intensity conditioning with fludarabine and thiotepa for second allogeneic transplantation of relapsed patients with AML (Q86046493)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23376820%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

title

Reduced-intensity conditioning with fludarabine and thiotepa for second allogeneic transplantation of relapsed patients with AML (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23376820%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23376820%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

author name string

C Schmoor

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23376820%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

M Waterhouse

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23376820%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

R Marks

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23376820%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

R Wäsch

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23376820%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

H Bertz

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23376820%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

J Finke

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23376820%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

publication date

4 February 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23376820%20AND%20SRC:MED&resulttype=core&format=json

Bone Marrow Transplantation

23 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23376820%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

volume

48

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23376820%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23376820%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

page(s)

901-907

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23376820%20AND%20SRC:MED&resulttype=core&format=json

The role of repeat transplantation of haemopoietic stem cells and adoptive immunotherapy in treatment of leukaemia relapsing following allogeneic transplantation

23 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.267

7 January 2021

Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.267

7 January 2021

A fludarabine, thiotepa reduced toxicity conditioning regimen designed specifically for allogeneic second haematopoietic cell transplantation after failure of previous autologous or allogeneic transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.267

7 January 2021

Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.267

7 January 2021

Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.267

7 January 2021

Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.267

7 January 2021

Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Societe Francaise de Greffe de Moelle (SFGM)

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.267

7 January 2021

Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.267

7 January 2021

Nonmyeloablative stem cell transplantation for the treatment of cancer and life-threatening nonmalignant disorders: past accomplishments and future goals

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.267

7 January 2021

Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.267

7 January 2021

A Novel GVHD-Prophylaxis with Low-Dose Alemtuzumab in Allogeneic Sibling or Unrelated Donor Hematopoetic Cell Transplantation: The Feasibility of Deescalation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.267

7 January 2021

IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.267

7 January 2021

Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.267

7 January 2021

Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.267

7 January 2021

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.267

7 January 2021

Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.267

7 January 2021

Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.267

7 January 2021

The role of thiotepa in allogeneic stem cell transplantation in patients with leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.267

7 January 2021

Immunosuppression with limited toxicity: the characteristics of nucleoside analogs and anti-lymphocyte antibodies used in non-myeloablative hematopoietic cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.267

7 January 2021

Second transplants for leukaemic relapse after bone marrow transplantation: high early mortality but favourable effect of chronic GVHD on continued remission. A report by the EBMT Leukaemia Working Party

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.267

7 January 2021

Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG +/- Ida) and second allogeneic stem cell transplant.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.267

7 January 2021

Relapse after allogeneic bone marrow transplantation for acute leukaemia: a survey by the E.B.M.T. of 117 cases

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.267

7 January 2021

Subcutaneous alemtuzumab vs ATG in adjusted conditioning for allogeneic transplantation: influence of Campath dose on lymphoid recovery, mixed chimerism and survival

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.267

7 January 2021

Different impact of intermediate and unfavourable cytogenetics at the time of diagnosis on outcome of de novo AML after allo-SCT: a long-term retrospective analysis from a single institution

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.267

7 January 2021

Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.267

7 January 2021

Loss of mismatched HLA in leukemia after stem-cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.267

7 January 2021

Relapse of leukemia with loss of mismatched HLA resulting from uniparental disomy after haploidentical hematopoietic stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.267

7 January 2021

Genome-wide profiling in AML patients relapsing after allogeneic hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.267

7 January 2021